Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease

Antioxidants and Redox Signaling

Volumn 24, Issue 7, 2016, Pages 376-391

  Deas, Emma ^a   Cremades, Nunilo ^b   Angelova, Plamena R ^a   Ludtmann, Marthe H R ^a   Yao, Zhi ^a   Chen, Serene ^b   Horrocks, Mathew H ^b   Banushi, Blerida ^c   Little, Daniel ^c   Devine, Michael J ^a   Gissen, Paul ^c   Klenerman, David ^b   Dobson, Christopher M ^b   Wood, Nicholas W ^a   Gandhi, Sonia ^a   Abramov, Andrey Y ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUTATHIONE; METAL ION; AMYLOID BETA PROTEIN; CASPASE 3; CASPASE 7; ION; METAL; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ARTICLE; BETA SHEET; CONTROLLED STUDY; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; ANIMAL; APOPTOSIS; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; ENZYME ACTIVATION; GENE DUPLICATION; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; NERVE CELL; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEINOSIS; STRUCTURE ACTIVITY RELATION;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL DIFFERENTIATION; ENZYME ACTIVATION; GENE DUPLICATION; GLUTATHIONE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; IONS; METALS; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RATS; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84959254675     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6343     Document Type: Article

References (54)

1. Abramov AY, Canevari L, and Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction, and oxidative stress in astrocytes, and death of neurons through activation of NADPH oxidase. J Neurosci 24: 565-575, 2004
2. Abramov AY, Jacobson J, Wientjes F, Hothersall J, Canevari L, and Duchen MR. Expression, and modulation of an NADPH oxidase in mammalian astrocytes. J Neurosci 25: 9176-9184, 2005
3. Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, and Schmidt HH. Evolution of NADPH Oxidase Inhibitors: selectivity, and mechanisms for target engagement. Antioxid Redox Signal 23: 406-427, 2015
4. Angelova PR, Horrocks MH, Klenerman D, Gandhi S, Abramov AY, and Shchepinov MS. Lipid peroxidation is essential for alpha-synuclein-induced cell death. J Neurochem 133: 582-589, 2015
5. Bilan DS, Pase L, Joosen L, Gorokhovatsky AY, Ermakova YG, Gadella TW, Grabher C, Schultz C, Lukyanov S, and Belousov VV. HyPer-3: a genetically encoded H(2)O(2) probe with improved performance for ratiometric, and fluorescence lifetime imaging. ACS Chem Biol 8: 535-542, 2013
6. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM, and Fernandez CO. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity, and fibrillation enhancement. J Am Chem Soc 128: 9893-9901, 2006
7. Brown DR. alpha-Synuclein as a ferrireductase. Biochem Soc Trans 41: 1513-1517, 2013
8. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, and Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511, 2002
9. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23: 1031-1038, 2002
10. Castellani RJ, Siedlak SL, Perry G, and Smith MA. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100: 111-114, 2000
11. Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, Klenerman D, Wood NW, Knowles TP, Alfonso C, Rivas G, Abramov AY, Valpuesta JM, Dobson CM, and Cremades N. Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation. Proc Natl Acad Sci U S A 112: E1994-E2003, 2015
12. Chinta SJ, Mallajosyula JK, Rane A, and Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons, and results in increased mitophagy in vivo. Neurosci Lett 486: 235-239, 2010
13. Chiti F, and Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366, 2006
14. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TP, Dobson CM, and Klenerman D. Direct observation of the interconversion of normal, and toxic forms of alpha-synuclein. Cell 149: 1048-1059, 2012
15. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, and Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 99: 14524-14529, 2002
16. Davies P, Moualla D, and Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS One 6: e15814, 2011
17. Davies P, Wang X, Sarell CJ, Drewett A, Marken F, Viles JH, and Brown DR. The synucleins are a family of redoxactive copper binding proteins. Biochemistry 50: 37-47, 2011
18. Deas E, Piipari K, Machhada A, Li A, Gutierrez-del-Arroyo A, Withers DJ, Wood NW, and Abramov AY. PINK1 deficiency in beta-cells increases basal insulin secretion, and improves glucose tolerance in mice. Open Biol 4: 140051, 2014
19. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, and Anandatheerthavarada HK. Mitochondrial import, and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures, and Parkinson disease brain. J Biol Chem 283: 9089-9100, 2008
20. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, and Kunath T. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2: 440, 2011
21. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garcon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonniere B, Strubi-Vuillaume I, Zahr N, Destee A, Corvol JC, Poltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, and Bordet R. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21: 195-210, 2014
22. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989
23. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, and Marsden CD. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2: 1219-1220, 1987
24. Dias V, Junn E, and Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 3: 461-491, 2013
25. Domijan AM, Kovac S, and Abramov AY. Lipid peroxidation is essential for phospholipase C activity, and the inositol-trisphosphate-related Ca(2)(+) signal. J Cell Sci 127: 21-26, 2014
26. Dryanovski DI, Guzman JN, Xie Z, Galteri DJ, Volpicelli-Daley LA, Lee VM, Miller RJ, Schumacker PT, and Surmeier DJ. Calcium entry, and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci 33: 10154-10164, 2013
27. Friedlich AL, Tanzi RE, and Rogers JT. The 5¢-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry 12: 222-223, 2007
28. Gandhi S, and Abramov AY. Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012: 428010, 2012
29. Geddes JF, Hughes AJ, Lees AJ, and Daniel SE. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism, and comparison with progressive supranuclear palsy, and Guamanian parkinsonism-dementia complex. Brain 116: 281-302, 1993
30. Halliwell B, and Whiteman M. Measuring reactive species, and oxidative damage in vivo, and in cell culture: how should you do it, and what do the results mean?. Br J Pharmacol 142: 231-255, 2004
31. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, and Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322: 383-393, 2002
32. Hung LW, Villemagne VL, Cheng L, Sherratt NA, Ayton S, White AR, Crouch PJ, Lim S, Leong SL, Wilkins S, George J, Roberts BR, Pham CL, Liu X, Chiu FC, Shackleford DM, Powell AK, Masters CL, Bush AI, O'Keefe G, Culvenor JG, Cappai R, Cherny RA, Donnelly PS, Hill AF, Finkelstein DI, and Barnham KJ. The hypoxia imaging agent CuII(atsm) is neuroprotective, and improves motor, and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med 209: 837-854, 2012
33. Junn E, and Mouradian MM. Human alpha-synuclein overexpression increases intracellular reactive oxygen species levels, and susceptibility to dopamine. Neurosci Lett 320: 146-150, 2002
34. Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, and Andersen JK. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging 28: 907-913, 2007
35. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, and Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489, 2003
36. Keelan J, Allen NJ, Antcliffe D, Pal S, and Duchen MR. Quantitative imaging of glutathione in hippocampal neurons, and glia in culture using monochlorobimane. J Neurosci Res 66: 873-884, 2001
37. Kovac S, Domijan AM, Walker MC, and Abramov AY. Seizure activity results in calcium-and mitochondriaindependent ROS production via NADPH, and xanthine oxidase activation. Cell Death Dis 5: e1442, 2014
38. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, and Lansbury PT, Jr. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular, and tubular protofibrils. J Mol Biol 322: 1089-1102, 2002
39. Lee FJ, Liu F, Pristupa ZB, and Niznik HB. Direct binding, and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15: 916-926, 2001
40. Macomber L, and Imlay JA. The iron-sulfur clusters of dehydratases are primary intracellular targets of copper toxicity. Proc Natl Acad Sci U S A 106: 8344-8349, 2009
41. Mosharov EV, Staal RG, Bove J, Prou D, Hananiya A, Markov D, Poulsen N, Larsen KE, Moore CM, Troyer MD, Edwards RH, Przedborski S, and Sulzer D. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26: 9304-9311, 2006
42. Nieto M, Gil-Bea FJ, Dalfo E, Cuadrado M, Cabodevilla F, Sanchez B, Catena S, Sesma T, Ribe E, Ferrer I, Ramirez MJ, and Gomez-Isla T. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 27: 848-856, 2006
43. Perry TL, and Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy, and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269-274, 1986
44. Reeve AK, Ludtmann MH, Angelova PR, Simcox EM, Horrocks MH, Klenerman D, Gandhi S, Turnbull DM, and Abramov AY. Aggregated alpha-synuclein, and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis 6: e1820, 2015
45. Santner A, and Uversky VN. Metalloproteomics, and metal toxicology of alpha-synuclein. Metallomics 2: 378-392, 2010
46. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841, 2003
47. Tabner BJ, Turnbull S, El-Agnaf O, and Allsop D. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Curr Top Med Chem 1: 507-517, 2001
48. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, and Schapira AH. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9: 2683-2689, 2000
49. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, and El-Agnaf OM. Detection of elevated levels of alphasynuclein oligomers in CSF from patients with Parkinson disease. Neurology 75: 1766-1772, 2010
50. Turnbull S, Tabner BJ, Brown DR, and Allsop D. Copperdependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106-126. Neurosci Lett 336: 159-162, 2003
51. Vaarmann A, Gandhi S, and Abramov AY. Dopamine induces Ca2+ signaling in astrocytes through reactive oxygen species generated by monoamine oxidase. J Biol Chem 285: 25018-25023, 2010
52. Volles MJ, and Lansbury PT, Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations, and occurs by a pore-like mechanism. Biochemistry 41: 4595-4602, 2002
53. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, and Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108: 4194-4199, 2011
54. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, and Montine TJ. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA, and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429, 1999